J2350 Injection, ocrelizumab, 1 milligrams
Also known as: ocrelizumab, Ocrevus, CD20 antibody
Injection of ocrelizumab, 1 milligram. A monoclonal antibody targeting CD20 on B cells for MS.
In Plain Language
MS medication; B cell immune suppressor
Clinical Context
Used for relapsing and primary progressive multiple sclerosis. Ocrelizumab selectively depletes CD20+ B cells involved in MS pathogenesis.
RVU Information
CPT J2350 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2350?
CPT J2350 (Injection, ocrelizumab, 1 milligrams) is a J Codes (Drugs) code. Injection of ocrelizumab, 1 milligram. A monoclonal antibody targeting CD20 on B cells for MS.
How is J2350 administered?
CPT J2350 is administered by a healthcare provider, typically via injection or infusion. Used for relapsing and primary progressive multiple sclerosis. Ocrelizumab selectively depletes CD20+ B cells involved in MS pathogenesis. It is used by Neurology, Immunology.
When is CPT J2350 used?
Used for relapsing and primary progressive multiple sclerosis. Ocrelizumab selectively depletes CD20+ B cells involved in MS pathogenesis.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.